Material Detail

ADCETRIS® A Treatment for Pediatric Classical Hodgkin Lymphoma (cHL)

ADCETRIS® A Treatment for Pediatric Classical Hodgkin Lymphoma (cHL)

ADCETRIS, in combination with a chemotherapy regimen called AVEPC (doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide), is FDA approved to treat children 2 years of age and older with previously untreated high-risk classical Hodgkin lymphoma.

Disciplines:

Health Sciences / Cancer / Cancer control

Go to Material

Bookmark / Add to Course ePortfolio

Create a Learning Exercise

Add Accessibility Information

Rate

rate this material with 1 stars

rate this material with 2 stars

rate this material with 3 stars

rate this material with 4 stars

rate this material with 5 stars

Add a Comment

Quality

User Rating
Comments
Learning Exercises
Bookmark Collection (1) Bookmark Collections
Course ePortfolios
Accessibility Info

Report Broken Link
Report as Inappropriate

More about this material

Material Type:: Reference Material
Date Added to MERLOT:: July 23, 2024
Date Modified in MERLOT:: July 31, 2024
Author:: Unknown (Know the author?)
Submitter:: Naomi Demessie
Primary Audience:: High School, College General Ed, College Lower Division, College Upper Division, Graduate School, Professional
Technical Format:: Website

Mobile Compatibility:: Not specified at this time
Language:: English
Cost Involved:: Unknown
Source Code Available:: Unknown
Creative Commons:: Unknown

Browse...

Disciplines with similar materials as ADCETRIS® A Treatment for Pediatric Classical Hodgkin Lymphoma (cHL)

Health Sciences / ... / Cancer control

People who viewed this also viewed

Other materials like ADCETRIS® A Treatment for Pediatric Classical Hodgkin Lymphoma (cHL)

Comments

Log in to participate in the discussions or sign up if you are not already a MERLOT member.